Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Theratechnologies Inc. (OTC: THERF).

Full DD Report for THERF

You must become a subscriber to view this report.


Recent News from (OTC: THERF)

3 Healthcare Tech Stocks To Watch In November
CORAL GABLES, FL / ACCESSWIRE / October 29,2018 / Frost & Sullivan will be hosting a Growth Innovation Leadership (GIL) briefing titled "2019 Healthcare Predictions Unleashed - Growth Opportunities, Technology, and Trends." The firm already states that Globally, 2019 will be a year of ...
Source: ACCESSWIRE IA
Date: October, 29 2018 12:25
Key events next week - healthcare
Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 26 2018 07:42
Theratechnologies Inc. (THERF) CEO Luc Tanguay on Q3 2018 Results - Earnings Call Transcript
Theratechnologies Inc. (THERF) Q3 2018 Results Earnings Conference Call October 4, 2018 08:30 AM ET Executives Denis Boucher - Vice President, Communications and Corporate Affaires Luc Tanguay - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chi...
Source: SeekingAlpha
Date: October, 04 2018 13:13
Theratechnologies reports Q3 results
Theratechnologies ( OTCPK:THERF ): Q3 GAAP EPS of C$0.00. More news on: Theratechnologies Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 04 2018 07:38
Gilead to launch generic versions of Epclusa and Harvoni
Gilead Sciences (NASDAQ: GILD ) announces that newly created subsidiary Asegua Therapeutics LLC will launch authorized generic versions of hepatitis C meds Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the U.S. More news on: Gilead Sciences, Inc., AbbVie Inc., P...
Source: SeekingAlpha
Date: September, 24 2018 08:42
Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved
Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticals’s ( ALNY ) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation . Left...
Source: SeekingAlpha
Date: September, 18 2018 10:45
EMA accepts Theratechnologies' Trogarzo marketing application
The European Medicines Agency (EMA) has accepted under accelerated review Theratechnologies' ( OTCPK:THERF ) marketing application seeking approval for Trogarzo (ibalizumab) for the treatment of multidrug-resistant HIV-1 infection in adults. More news on: Theratechnologies Inc., Healthca...
Source: SeekingAlpha
Date: September, 14 2018 08:38
Premarket analyst action - healthcare
Theratechnologies ( OTCPK:THERF ) initiated with Sector Perform rating with a C$11 (flat) price target at RBC. More news on: Theratechnologies Inc., Tocagen Inc, Vaccinex, Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 04 2018 09:06
Theratech nearing the finish line with Trogarzo in Europe
Theratechnologies ( OTCPK:THERF -0.2% ) announces that it has filed a marketing application in Europe seeking approval for Trogarzo (ibalizumab-uiyk) for the treatment of adults with HIV-1 infection. More news on: Theratechnologies Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 20 2018 10:52
Your Daily Pharma Scoop: Puma Progresses, Kala In Phase 3, Teva Fails
Stocks in the News: PBYI, KALA Puma Bio's Nerlynx marketing application in Canada under review Puma Biotechnology's ( PBYI ) New Drug Submission (‘NDS) for NERLYNX ( neratinib ) for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer is...
Source: SeekingAlpha
Date: August, 02 2018 06:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-186.31546.16966.326.1124,228
2018-12-176.466.316.496.2451,720
2018-12-146.376.49186.70616.3065,954
2018-12-136.366.276.376.279,500
2018-12-126.35186.356.406.3023,299

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-188,39224,22834.6376Cover
2018-12-1714,78851,72028.5924Cover
2018-12-143,66665,9545.5584Cover
2018-12-131,8009,50018.9474Cover
2018-12-1235023,2991.5022Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on THERF.


About Theratechnologies Inc. (OTC: THERF)

Logo for Theratechnologies Inc. (OTC: THERF)

Not available

 

Contact Information

 

 

Current Management

  • Luc Tanguay / President, CEO
  • Marie Noel Colussi / VP, Fin.
  • Andrea Gilpin Gilpin / VP, Investor Rel.
  • Paul Pommier / Chairman

Current Share Structure

  • Market Cap: $454,907,258 - 03/16/2018
  • Issue and Outstanding: 61,010,603 - 11/30/2012

 


Recent Filings from (OTC: THERF)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (OTC: THERF)

Daily Technical Chart for (OTC: THERF)


Stay tuned for daily updates and more on (OTC: THERF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: THERF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in THERF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of THERF and does not buy, sell, or trade any shares of THERF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/